Cryosite Limited AI Stock Analysis
Want to see AU:CTE full AI Analyst Report?
Cryosite Limited (CTE) AI Stock Analysis
Cryosite Limited
(ASX:CTE)
Cryosite scores in the middle of the range. The core business is genuinely improving — six consecutive years of revenue growth, widening operating margins and operating cash flow that exceeds reported profit — but the balance sheet is the key risk, with debt tripling to $7.7 million, leverage above 1.5x a thin equity base, and free cash flow swinging to roughly -$8.1 million during an aggressive capital investment cycle. Technicals are supportive, with the price above all major moving averages and a positive MACD, although the advance looks extended in the near term. Valuation is the main drag: a P/E of ~27 with no dividend leaves limited margin for error should the investment program fail to convert into incremental revenue and positive free cash flow.
Cryosite Limited (CTE) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 59.55M
- Dividend Yield
- ―
- Average Volume (3M)
- 6,047
- Price to Earnings (P/E)
- 26.6
- Beta (1Y)
- -0.03
- Revenue Growth
- 18.31%
- EPS Growth
- 18.65%
- Country
- Australia
- Employees
- 27
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Cryosite Limited Business Overview & Revenue Model
Company Description
Cryosite Limited, founded in 1999 and headquartered in South Granville, Australia, specializes in providing outsourced logistics and storage solutions to the life sciences industry within Australia. The company operates through two distinct divisions...
How the Company Makes Money
null
Cryosite Limited Financial Statement Overview
Summary
Earnings quality is the standout: revenue has grown every year since FY2021, reaching $16.7 million in FY2026 (up ~18%), with operating margin expanding to ~18.9% and net margin to ~13.4% (Income Statement 76). Operating cash flow of $2.7 million exceeds net income, confirming good earnings conversion, but free cash flow swung to roughly -$8.1 million on a large capital program (Cash Flow 52). That build-out was debt-funded, tripling borrowings to $7.7 million and lifting debt-to-equity to ~1.59x on a thin equity base of $4.9 million (Balance Sheet 50). A slipping gross margin (from ~63% to ~57%) adds to the caution.
Income Statement
76PositiveBalance Sheet
50NeutralCash Flow
52Neutral| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 16.70M | 16.70M | 14.12M | 12.61M | 11.94M | 11.76M |
| Gross Profit | 9.51M | 9.51M | 8.89M | 7.99M | 6.48M | 6.27M |
| EBITDA | 3.99M | 4.07M | 3.41M | 3.04M | 2.30M | 2.40M |
| Net Income | 2.23M | 2.23M | 1.88M | 1.84M | 1.41M | 1.36M |
Balance Sheet | ||||||
| Total Assets | 25.97M | 25.97M | 19.46M | 19.71M | 22.65M | 21.50M |
| Cash, Cash Equivalents and Short-Term Investments | 2.24M | 2.24M | 5.06M | 4.70M | 5.73M | 5.34M |
| Total Debt | 7.72M | 7.72M | 2.27M | 2.44M | 2.61M | 849.76K |
| Total Liabilities | 21.12M | 21.12M | 17.07M | 18.26M | 19.86M | 19.64M |
| Stockholders Equity | 4.85M | 4.85M | 2.39M | 1.45M | 2.78M | 1.86M |
Cash Flow | ||||||
| Free Cash Flow | -8.14M | -8.14M | 1.48M | 2.44M | 1.19M | 1.63M |
| Operating Cash Flow | 2.73M | 2.73M | 2.06M | 2.90M | 1.49M | 2.49M |
| Investing Cash Flow | -10.87M | -10.87M | -420.00K | 727.00K | -1.33M | -863.19K |
| Financing Cash Flow | 5.33M | 5.33M | -1.29M | -3.50M | -768.00K | -148.99K |
Cryosite Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CTE, the sentiment is Positive. The current price of 1.22 is below the 20-day moving average (MA) of 1.22, above the 50-day MA of 1.20, and above the 200-day MA of 1.17, indicating a neutral trend. The MACD of 0.01 indicates Positive momentum. The RSI at 55.81 is Neutral, neither overbought nor oversold. The STOCH value of -0.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:CTE.
Cryosite Limited Peers Comparison
Overall Rating
AU:SHL72Outperform
AU:ACL66Neutral- AU:CTE63Neutral
AU:MVF53.5Neutral
AU:HLS51Neutral
AU:GSS39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| AU:SHL | 72Outperform | AUD 9.85B | 16.17 | 7.20% | 5.43% | 14.40% | 15.11% |
| AU:ACL | 66Neutral | AUD 621.11M | 27.10 | 15.80% | 3.88% | -0.90% | -25.09% |
| AU:CTE | 63Neutral | AUD 59.55M | 26.64 | 52.84% | ― | 18.31% | 18.65% |
| AU:MVF | 54Neutral | AUD 294.17M | 39.27 | 2.95% | 3.33% | -0.90% | -70.25% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| AU:HLS | 51Neutral | AUD 392.14M | -1.00 | -114.08% | ― | 2.16% | 21.05% |
| AU:GSS | 39Underperform | AUD 16.35M | -1.17 | -35.10% | ― | -9.10% | 31.75% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:CTE | Cryosite Limited | 1.22 | 0.02 | 1.67% | |
| AU:HLS | Healius Limited | 0.57 | -0.33 | -36.46% | |
| AU:GSS | Genetic Signatures Ltd. | 0.07 | -0.22 | -75.59% | |
| AU:SHL | Sonic Healthcare Limited | 19.89 | -0.06 | -0.29% | |
| AU:ACL | Australian Clinical Labs Ltd | 3.35 | 0.80 | 31.58% | |
| AU:MVF | Monash IVF Group Ltd | 0.75 | 0.17 | 29.53% |
Cryosite Limited Corporate Events
Cryosite doubles storage footprint and posts record FY26 results
Cryosite Limited has more than doubled its storage and warehousing footprint to over 4,200 square metres after acquiring a second freehold facility in Auburn and extending its principal cool room at its South Granville headquarters. The company aims...
Cryosite files 2026 corporate governance statement and ASX Appendix 4G
Cryosite Limited has lodged its corporate governance statement for the year ended 30 June 2026 with the ASX and published it on its website, detailing how it adheres to the ASX Corporate Governance Council’s principles and recommendations. The statem...
Cryosite boosts profit and doubles storage capacity as it withholds dividend
Cryosite Limited reported a strong improvement in trading conditions for the year ended 30 June 2026, with revenue rising 18% to $16.7 million and net profit after tax increasing 19% to $2.24 million. Key profitability metrics also advanced, as EBITD...
Cryosite lifts profit on higher utilisation and prepares for next growth phase
Cryosite reported unaudited FY2026 revenue of $16.7 million, up 18%, with EBITDA rising 27% to $4.3 million and margins expanding as utilisation of its Ferndell Street headquarters improved. Net profit after tax increased 20% to $2.3 million, with ea...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 20, 2026